Enzymes from the PDE (phosphodiesterase) 4 cAMP-specific PDE family are crucial for the maintenance of compartmentalized cAMP responses in many cell types. Regulation of PDE activity can be achieved via post-translational modification such as phosphorylation by ERK (extracellular-signal-regulated kinase) MAPKs (mitogen-activated protein kinases) and PKA (protein kinase A). In the present paper, we report for the first time that PDE4 isoforms from the PDE4A and PDE4D subfamilies can be selectively modified by SUMO (small ubiquitin-related modifier). We have identified a single SUMO site within a consensus tetrapeptide motif, ψKXE (where ψ represents a hydrophobic residue), which lies in the catalytic unit of these enzymes. SUMO modification of PDE4 at this site was observed upon overexpression of the SUMO E3 ligase PIASy [protein inhibitor of activated STAT (signal transducer and activator of transcription) Y] in HEK (human embryonic kidney)-293 cells and we identify PIASy as a novel binding partner for long PDE4 isoforms. Site-directed mutagenesis of the acceptor lysine residue ablated conjugation of PDE4 with SUMO, suggesting the presence of a single SUMO site in the first subdomain of the conserved PDE4 catalytic unit. This observation was supported by both cell-free in vitro SUMOylation assays and analysis of SUMOylated spot-immobilized peptide arrays. SUMO modification of long PDE4 isoforms serves to augment their activation by PKA phosphorylation and repress their inhibition by ERK phosphorylation. Following ligation of β-adrenergic receptors, SUMOylation of PDE4 isoforms sufficiently amplified PKA-stimulated PDE4 activity to reduce markedly the PKA phosphorylation status of the β 2 -adrenergic receptor. These results highlight a new means whereby cells might achieve the selective regulation of the activity of cAMP-specific PDE4 enyzmes.
INTRODUCTION
Signal transduction via the cAMP pathway is known to be ubiquitous and represents a major line of communication between many organisms and their environment [1] . Messages from a plethora of cell-surface receptors are translated into specific downstream biological processes through the dual action of adenylate cyclases [2] that synthesize the second messenger cAMP and its various effector proteins, namely PKA (protein kinase A) [1] , EPAC (exchange protein activated by cAMP) [3] and cyclic-nucleotide-gated ion channels [4] . Signal termination is mediated by a group of proteins, the cyclic nucleotide PDEs (phosphodiesterases), which represent the sole route of cAMP degradation [5] .
Recent technological advances in the development of genetically encoded cAMP reporters have provided a unique insight into the pivotal role of PDEs and, particularly, PDE4 cAMP-specific enzymes in the spatial and temporal regulation of cAMP signals [6, 7] . Compartmentalization of PDEs to discrete intracellular locations allows cAMP gradients to be formed and shaped, with such spatial regulation being crucial for normal cell function [5, 6] .
Cells can express a defined subset of PDEs from the 11 different families, of which eight have the ability to hydrolyse cAMP [8] . The cAMP-specific PDE4 family has become of increased interest because of its implication in a number of disease states [9, 10] and its identification as a therapeutic target. Additionally, it has been discovered that these enzymes play a critical role in determining compartmentalized cAMP signalling in cells due to their isoform-specific N-terminal regions that allow them to be targeted to distinct signalling complexes [5, 6, 11] . The activity of PDE4s is constitutive, but can be altered by a number of post-translational events [5] . Long PDE4 isoforms contain a PKA phosphorylation motif in their regulatory UCR (upstream conserved region) 1, and phosphorylation by PKA within this domain causes activation of catalytic activity and a change in enzyme conformation [12, 13] . Such an arrangement serves to produce an orchestrated 'pulse' of cAMP that is temporally and spatially restricted by this feedback control mechanism coupled to intracellular targeting [14] . All PDE4s, except those in the PDE4A subfamily, also contain an ERK (extracellular-signal-regulated kinase) MAPK (mitogen-activated protein kinase) consensus phosphorylation motif in their conserved catalytic region [15] . Phosphorylation at this target site is facilitated by the ERK docking and specificity sites, which straddle the target serine [15] . In contrast with the action of PKA phosphorylation, which activates long PDE4 isoforms [12] , the functional consequence of ERK phosphorylation on long PDE4 isoforms is to cause inhibition [16] .
One challenge that faces researchers in the field is to decipher which signals regulate the formation of specific signalling complexes that include PDE4s. The isoform PDE4D5, for instance, can bind the scaffolding proteins RACK1 (receptor for activated C-kinase 1) [17] and β-arrestin [18] in a mutually exclusive fashion [19] . As PDE4D5 can be anchored at other locations outwith the influence of these scaffolds, these scaffold proteins sequester only a portion of the total PDE4D5 pool at any one time. During β-adrenergic stimulation, the translocation of the β-arrestin-PDE4D5 complex from the cytosol to the β 2 AR (β 2 -adrenergic receptor) receptor at the plasma membrane serves to co-ordinate a dual-desensitization event that effectively prepares the receptor for another round of agonist challenge [19, 20] . The efficacy of receptor desensitization depends on the β-arrestin-mediated delivery of sufficient, suitably activated, PDE4D5 to the site of cAMP synthesis at the plasma membrane [21] . This action can be facilitated by the agonistdependent ubiquitination of PDE4D5 by the β-arrestin-scaffolded E3 ligase Mdm2 (murine double minute 2) [22] . In this, monoubiquitination of PDE4D5 at a single lysine residue in UCR1 triggers a cascade of polyubiquitination occurring on three lysine residues in the unique N-terminal region of PDE4D5. Such modification, although not affecting the activity of PDE4D5, serves to enhance its binding to β-arrestin [22] .
In the last decade, SUMOylation has emerged as a novel way in which proteins can be modified to change their intracellular localization, binding partner profile and activity [23] . SUMO (small ubiquitin-related modifier) proteins are conjugated on to substrates via a multi-step energy-requiring process involving E1 SUMO activators, E2 conjugation enzymes and E3 SUMO ligases [24] . SUMO conjugation is highly lysine-specific with the SUMO conjugation site invariably residing within a consensus tetrapeptide, ψKXE (ψ represents a hydrophobic residue). It is thought that this sequence orientates the catalytic region of the E2-conjugating enzyme UBC9 (ubiquitin-like protein SUMO-conjugating enzyme 9) towards the target lysine [25] . Added fidelity of UBC9-substrate interaction can depend on a negative patch of amino acids located some four residues upstream of the acceptor lysine residue. This can take the form of either aspartate or glutamate residues [26] or an SP (Ser-Pro) motif that is phosphorylated before SUMOylation [27] .
Following sequence analysis of PDE4 isoforms, we have identified a putative SUMO consensus motif within the conserved PDE4 catalytic region. Intriguingly, only enzymes from PDE4A and PDE4D subfamilies contain the putative acceptor lysine residue at cognate positions 358 in PDE4A4 and 323 in PDE4D5. In the present paper, we report, for the first time, that SUMOylation may provide a novel means by which PDE4 isoforms can be modified and regulated. A functional output of PDE4 SUMOylation appears to be in amplifying long-form PDE4 activation by PKA phosphorylation, while simultaneously protecting PDE4 long forms from inhibitory input elicited through phosphorylation by ERK.
EXPERIMENTAL

Materials
PolyFect transfection reagent was from Qiagen. Protease inhibitor tablets were from Roche. VSV (vesicular stomatitis virus)-affinity agarose beads and anti-VSV monoclonal antibodies were purchased from Sigma. In vitro SUMOylation kits were purchased from Biomol. Plasmid DNA was produced using the QIAprep ® Spin Miniprep kit from Qiagen.
Site-directed mutagenesis
The PDE4D5 SUMO mutant (K323R), was constructed using the QuikChange ® site-directed mutagenesis kit (Stratagene). The 5 -and 3 -primers designed for the PDE4D5 SUMO mutant (PDE4D5-K323R) were as follows with the mutated nucleotides underlined: forward, 5 -CCCAAGGTTTGGAGTTCGA-ACTGAACAAGAAGATGTCC-3 , and reverse, 5 -GGACATC-TTCTTGTTCAGTTCGAACTCCAAACCTTGGG-3 . All constructs were verified by DNA sequencing before use.
Purification of recombinant fusion proteins
Competent Escherichia coli BL21(DE3) pLysS cells transformed with the appropriate pMAL plasmid, were grown directly in 30 ml of sterilized LB (Luria-Bertani) medium supplemented with 100 μg/ml ampicillin, overnight in an orbital shaking incubator at 37
• C. Then, 450 ml of sterilized LB medium, supplemented with 100 μg/ml ampicillin, was inoculated with the overnight culture and grown in the orbital shaker at 37
• C for 1-2 h. A 1 ml sample of culture was removed and placed into a plastic cuvette and the attenuance was measured at 600 nm (D 600 ) against an LB medium control. Expression of the fusion protein was induced with 0.2 mM IPTG (isopropyl β-D-thiogalactoside) when an D 600 of 0.6-1 was achieved. Expression of the target protein was undertaken for 4 h in an orbital shaker set at 30
• C. Every 1 h, 1 ml samples of LB medium were removed to monitor protein expression. The samples were centrifuged at 10 000 g for 10 min and the pellet was resuspended in SDS sample buffer for analysis by SDS/PAGE (NuPage, Invitrogen) and Coomassie Blue staining. The cells were then harvested by centrifugation at 5000 g for 10 min. The cells were resuspended in 12 ml of 50 mM Tris/HCl (pH 8.0), 10 mM NaCl and 10 mM 2-mercaptoethanol containing a 1× solution of protease inhibitor cocktail tablets. The resuspended cells were then frozen at − 80
• C and thawed on ice when required. Lysozyme was added at a final concentration of 1 mg/ml and the cell suspension was subjected to sonication to achieve sufficient cell lysis. A final concentration of 0.05 % NP-40 (Nonidet P40) was added to aid cell lysis and the subsequent cell debris removed by centrifugation at 10 000 g for 15 min. Then, 1 ml of amylose resin (New England BioLabs) was pre-equilibrated with resuspension buffer (pH 7.4) containing 0.05 % NP-40. The cell supernatant was applied to the preequilibrated resin and incubated end-over-end for 1 h at 4
• C to bind the expressed fusion protein. The resin was collected by centrifugation at 2000 g for 2 min and washed three times with 750 μl of resuspension buffer (pH 7.4) containing 0.05 % NP-40. The fusion protein was eluted from the amylose resin with 500 μl of 10 mM maltose and 50 mM Tris/HCl (pH 8.0) by incubating end-over-end for 20 min at 4
• C. The eluted fractions were pooled and dialysed using Pierce Slide-A-Lyser dialysis cassettes against three 650 ml volumes of 100 mM NaCl, 50 mM Tris/HCl (pH 8.0) and 5 % (v/v) glycerol for 1 h each at 4
• C. The purified fusion protein was frozen on solid CO 2 and stored in 50 μl aliquots at − 80
• C. 
Immunoprecipitation and Western blotting
Cells were transiently transfected with wild-type β-arrestin1-FLAG, PDE4D5-VSV or a SUMO-defective PDE4D5-K323R-VSV. At 48 h after transfection, cells were lysed using a 3T3 lysis buffer containing 20 mM Hepes (pH 7.4), 50 mM NaCl, 50 mM NaF, 10 % (v/v) glycerol, 1 % (w/v) Triton X-100, 10 mM EGTA, 30 mM sodium pyrophosphate and protease inhibitor cocktail. Cell lysates were pre-cleared with Protein G beads and then used for immunoprecipitation of VSV-tagged proteins. Cell lysates were incubated with VSV-affinity agarose beads for 2 h at 4
• C. After centrifugation at 18 000 g for 3 min, beads were washed three times with the lysis buffer. Laemmli sample buffer was used to elute the immunoprecipitated VSV-fusion proteins and the resulting material was resolved by NuPAGE (Invitrogen). Proteins were transferred on to nitrocellulose membranes and subjected to Western blotting with detection by ECL (enhanced chemiluminescence) (Pierce).
PDE activity assay
PDE activity was measured using a radioactive cAMP hydrolysis assay that has been described previously [28] . [8- 3 H]cAMP was from GE Healthcare and unlabelled cAMP was from Sigma.
In vitro PKA and ERK phosphorylation assay
Kinase phosphorylation assays were undertaken using purified PKA catalytic subunits (Promega) and purified ERK2 (Millipore). Then, 1 μg of fusion protein and recombinant kinase were diluted in phosphorylation buffer [100 mM Tris/HCl (pH 7.5), 0.2 mM ATP, 10 mM MgCl 2 , 30 mM 2-mercaptoethanol, 20 % (v/v) glycerol and 10 mM Calyculin A]. The reaction mixture was incubated at 30
• C for 30 min. The reaction was stopped by the addition of 12.5 μl of 5× SDS sample buffer. The reaction tubes were mixed and heated at 70
• C for 10 min on a heating block. The tubes were then centrifuged at 13 000 g for 1 min and the sample was subjected to SDS/PAGE and transferred on to a nitrocellulose membrane. In all cases, the extent of PDE4D5 phosphorylation was corrected for by determining the immunoreactive amount of target protein.
Pull-down assays
MBP (maltose-binding protein)-PDE4D5 fusion proteins (500 μl of 2 μM) were mixed with 100 μl of a slurry of 50 % (v/v) PBSwashed Amylose resin (GE Healthcare) for 2 h at 4
• C. The beads were pelleted by centrifugation at 14 000 g for 1 min and washed twice with PBS containing 1 % (w/v) Triton X-100 before the addition of equimolar amounts of β-arrestin-GST (glutathione transferase) fusion protein in a 1 ml solution of PBS and Triton X-100 containing 5 mM dithiothreitol. After 2 h of incubation at 4
• C, the beads were collected and washed three times with PBS and eluted in 100 μl of 2× Laemmli buffer [29] . Eluates were resolved by SDS/PAGE (4-12 % gels), and the GST-fusion proteins were detected by immunoblotting.
SPOT synthesis of peptides
Peptide libraries were produced by automatic SPOT synthesis and synthesized on continuous cellulose membrane supports on Whatman 50 cellulose membranes using Fmoc (fluoren-9-ylmethoxycarbonyl) chemistry with the AutoSpot-Robot ASS 222 (Intavis Bioanalytical Instruments) as described previously by us [30] .
In vitro expression and SUMOylation of PDE4
In vitro transcription/translation of PDE4 was performed using 1 μg of plasmid DNA and a wheat-germ-coupled transcription/translation system according to the manufacturer's instructions (Promega) and as described previously by us [31] . [ 35 S]Methionine (GE Healthcare) was used in the reaction mixtures to generate radiolabelled PDE4 proteins before 1 μl of [ 35 S]methionine-labelled PDE4 was incubated at 37
• C for 4 h in a 10 μl reaction mixture containing an ATP-regenerating system (50 mM Tris/HCl, pH 7.6, 5 mM MgCl 2 , 2 mM ATP, 10 mM creatine phosphate, 3.5 units/ml creatine kinase and 0.6 unit/ml inorganic pyrophosphatase), 0.1 μM SAE (SUMOactivating enzyme) 1/SAE2, 4.4 μM UBC9, 9 μM SUMO-1 or 2, EDTA-free protease inhibitors (Roche) and 5 mM dithiothreitol. Reactions were terminated with SDS sample buffer containing 2-mercaptoethanol. Reaction products were fractionated by SDS/PAGE (10 % or 8 % gels). Dried gels were analysed using a PhosphoImager (Fuji BAS 1500, MacBAS software).
In vitro SUMOylation assay
A SUMO Kit (Biomol) was used and the procedure carried out according to the manufacturer's instruction for the SUMOylation of MBP-or GST-fusion proteins. Peptide arrays that included the putative SUMO site on PDE4A4, PDE4B2, PDE4C2 and PDE4D5 were synthesized and used in the same SUMOylation assay. The SUMO assay mixture was incubated with array membranes for 30 min at 30
• C with shaking. Membranes were washed with TBST (Tris-buffered saline with Tween 20: 137 mM NaCl, 20 mM Tris/HCl, pH 7.6, and 0.1 % Tween 20) before the SUMOylated moieties on the peptide array were probed using an antibody specific for SUMO. Control arrays were carried out with SUMO assay mixtures that did not contain UBC9, the E2 ligase for SUMO conjugation.
cAMP measurements
The concentration of cAMP in lysates extracted from COS1 cells was measured using a cAMP competitive EIA assay kit (Zymed).
RESULTS
PDE4A and PDE4D subfamilies contain a SUMO consensus motif
Previous sequence analysis of PDE4s has uncovered regions of highly conserved sequence that exist in all PDE4 isoforms, namely the catalytic unit, UCR1 and UCR2 [4, 32] . Other regions, such as the C-terminal tail, are unique to specific PDE4 subfamilies, and the extreme N-terminal region that, with one exception (where the N-terminus of PDE4B5 is identical with that of PDE4D6 [33] ), is unique to each individual isoform [32] .
Our analysis of the PDE4 catalytic region sequence indicated a putative SUMO consensus motif that is found in the PDE4A and PDE4D subfamilies and not either of the PDE4B and PDE4C subfamilies (Figures 1a and 1b) . This motif is akin to the so-called 'negatively charged amino acid-dependent SUMOylation motif' (NDSM) that has been defined as ψKXEXX(D/E)(D/E), where ψ represents a hydrophobic residue and X represents residues that are less well conserved [26] . Using example long isoforms from each of these two PDE4 subfamilies, the putative SUMO octapeptide NDSM commences at Val 357 in PDE4A4 and Val 322 in PDE4D5 (Figure 1a ). An inspection of PDB entries revealed that the peptide is present at the N-terminus of the structurally defined core catalytic domain region in both of the currently available PDE4A structures and seven of the 22 PDE4D structures [34] . In each structure, the proposed SUMO acceptor lysine residue is located on a region of prominently exposed coil immediately preceding helix-1 located in subdomain-1. Moreover, in the majority of these structures, the local conformation of the peptide backbone spanning the core ψKX(D/E) region closely resembles the corresponding region in the SUMOylated RanGAP1 (Ran GTPase-activating protein 1), as seen in its crystal structure ( Figure 1d ) complexed with UBC9 and a ligase fragment from Nup358 [35] . The similarity between RanGAP1 and PDE4A/D in the presentation of this motif strongly suggested that these PDE4 isoforms should be able to dock UBC9 successfully. Indeed, superimposition of the PDE4 structures on to the SUMORanGAP1-UBC9 complex (Figure 1d ) confirmed that the acidic residue at position 4 is well poised to form a salt bridge to Lys 74 in UBC9, whereas the hydrophobic residue at position 1 fits into a shallow basin on the surface of UBC9 proximal to Ala 129 . There is a cluster of basic residues exposed on the surface of UBC9 close to Lys 74 that might, in principle, interact favourably with the paired C-terminal acidic residues of the NDSM. The SUMOylation sequence in RanGAP1 lacks these acidic residues and does not make contact with this region of the SUMOconjugating enzyme, however. In contrast, the putative PDE4A and PDE4D SUMOylation motifs do possess a pair of adjacent acidic residues at positions 6 and 7. These are located at the Nterminal end of helix-1 and are also prominently surface-exposed.
Intriguingly, although isoforms from the PDE4B and PDE4C subfamilies exhibit the hydrophobic and acidic residues of the core SUMO motif, plus both residues of the acidic patch and a similar conformational organization, the lysine SUMO-acceptor residue at position 2 is replaced by either an asparagine or a glutamine residue in these two subfamilies respectively (Figure 1a ).
This analysis indicates that only members of the PDE4A and PDE4D subfamilies should have the potential to be subject to modification by SUMOylation.
PDE4A and PDE4D peptide arrays are selectively SUMOylated in vitro
We have used peptide arrays on solid support coupled with in vitro ubiquitination assays to define the sites on PDE4D5 where Mdm2-catalysed ubiquitination occurs [33] . Recently, such an approach has been used employing in vitro SUMOylation assays to gain insight into the selectivity and fidelity of SUMO conjugation using RanGAP1 as a substrate [36] , and we have used it to define sites for Mdm2-catalysed ubiquitination of PDE4D5 [22] . Such studies indicated that SUMOylation of RanGAP1 depends upon the amino acids that make up the core and flanking regions of the NDSM.
We thus adopted this methodology to determine whether the differences in sequence seen between PDE4 subfamilies isoforms from four different subfamilies, namely PDE4A, PDE4B, PDE4C and PDE4D. Putative SUMOylation sites are in uppercase letters and successful conjugation of recombinant SUMO to immobilized peptides using an in vitro SUMO assay kit is represented by dark spots. (d) Structural detail of RanGAP1 (magenta) conjugated to SUMO (orange) and complexed to UBC9 (green) from crystal structure 1Z5S (PDB code) [35] . The PDE4A and PDE4D SUMOylation peptides (respectively yellow and blue) are shown superimposed from crystal structures 2QYK and 2FM0 (PDB codes) [34, 55] . The local backbone conformation of the PDE4 SUMOylation peptides closely resembles the RanGAP1 structure. A cluster of basic residues on the surface of UBC9 may facilitate interaction with paired C-terminal acidic residues in the more extended
NDSM: ψKX(D/E)XX(D/E)(D/E).
RanGAP1 lacks these residues, whereas the PDE4A and PDE4D peptides possess paired EE and ED residues at positions 6 and 7. Although surface-exposed, the location of these residues on helix-1 of the PDE4 core catalytic domain suggested that they are unlikely to facilitate SUMOylation by contributing to a docking interface for UBC9. might result in differential SUMOylation of the cognate catalytic regions (Figure 1c ). Peptide arrays of overlapping 25-mer peptides, sequentially shifted by five amino acids and spanning the entire indicated PDE4 isoform sequence, were incubated with a SUMOylation assay mixture before detection of SUMO conjugation using an anti-SUMO antibody. Dark spots represent positive areas of SUMO conjugation, whereas clear spots are negative for the modification by SUMO (Figure 1c ). Doing this, we observed that, whereas no signal was observed using the PDE4B2 and PDE4C2 arrays, positive signals were obtained using the PDE4A4 and PDE4D5 arrays (Figure 1c) . Clearly, the inclusion of a putative acceptor lysine residue within the SUMO core consensus NDSMs of both PDE4A4 and PDE4D5 allows SUMO modification of the immobilized peptides that contain it, whereas cognate peptides from PDE4B2 and PDE4C2 do not appear to allow conjugation to SUMO.
PDE4A and PDE4D long forms are selectively SUMOylated in HEK-293 cells
To determine whether the differential SUMOylation of PDE4 isoforms could be observed in cells, we transiently transfected PDE4A4, PDE4B2, PDE4C2 and PDE4D5 into HEK-293 cells. Under resting conditions, we could not detect (Figure 2a ) the 25-kDa 'band shift' that typically characterizes the covalent addition of SUMO to an acceptor protein [37] .
However, protein SUMOylation is dually controlled by action of the E2 conjugating enzyme UBC9 and by SUMO-specific proteases that rapidly cleave the covalent bond between SUMO and the substrate [23] . The dynamic nature of this relationship means that, under steady-state conditions, only a small proportion of a protein is SUMOylated at any one time and this, invariably, seriously hampers biochemical detection of SUMO-modified proteins (see, e.g., [23] ). Although endogenous levels of SAE1 and SAE2 and UBC9 are usually sufficient to allow SUMOylation to occur in cells, it has been shown that the detection of SUMOylated species in cells can be facilitated when an E3 ligase also forms part of the SUMOylation complex [23] . This markedly increases both the specificity and fidelity of SUMOylation in vivo. Thus, to circumvent the universal difficulties encountered in monitoring endogenously SUMOylated proteins, investigators have routinely amplified SUMOylation by transiently co-expressing the SUMO E3 ligase, PIASy [protein inhibitor of activated STAT (signal transducer and activator of transcription) Y] [38, 39] . In the present study, we have utilized the same approach by coexpressing HA (haemagglutinin)-tagged PIASy, together with representative PDE4 isoforms from all four subfamilies. Using this method, we were able to visualize an additional more slowly migrating immunoreactive PDE4 species that appeared to be approx. 25 kDa larger than that of the native forms of both PDE4A4 and PDE4D5 (Figure 2a) . In marked contrast with this, no such slower migrating species was evident upon co-transfection of HA-tagged PIASy with either PDE4B2 or PDE4C2 (Figure 2a) . This suggests that, in agreement with the peptide array data (Figure 1c ) and bioinformatics analysis (above), both PDE4A and PDE4D subfamilies are able to become SUMOylated, whereas PDE4B and PDE4C subfamilies cannot. Consistent with the notion that the retarded mobility was due to SUMOylation, only the more slowly migrating species was recognized by antibodies against SUMO1 (Figure 2a) , showing that PDE4A4 and PDE4D5 can indeed be SUMOylated in a cellular context. Surprisingly, the short PDE4D1 isoform could not be SUMOylated in the same manner as PDE4D5 even although it contains the putative SUMO octapeptide (Figure 2b) . However, in subsequent analyses, utilizing immunopurified forms of PDE4D5 and PDE4D1, we found that the E3 ligase PIASy associated only with the long PDE4D5 isoform and not the 35 S before being incubated in a SUMOylation assay mixture that contained either SUMO1 (S1), SUMO2 (S2) or no SUMO (Un). SUMOylation assay mixtures containing SP100 were included as a positive control. Higher-molecular-mass bands, which represent SUMOylated PDE4D3 and PDE4D5 bands are indicated by *. SUMOylated positive control SP100 are indicated by ‡.
short PDE4D1 isoform (Figure 2c) . In order to investigate the basis of this selective interaction, we probed GST-fusion proteins of distinct PDE4D regions (Figure 2d ) and full-length peptide arrays of PDE4D5 and PDE4D1 (Figure 2e) for the ability to associate with HA-PIASy. Clearly, two areas of association exist in PDE4D5 (Figure 2e ) for the docking of PIASy, one in the longisoform-specific UCR1 domain and one within the conserved catalytic region. As PDE4D1 and other short PDE4 isoforms do not contain UCR1 (Figure 2e ), we suggest that the lack of one of the PIASy-interaction sites may underpin the selective nature of SUMOylation for long PDE4 isoforms. This notion is supported by the GST-pull-down results (Figure 2d ), which are consistent with the notion that both sites are required for the efficient docking of the SUMO E3 PIASy.
PDE4D isoforms are selectively SUMOylated in vitro
To reinforce the premise that the long PDE4D subfamily isoforms are SUMO substrates, we incorporated PDE4D3 and PDE4D5 into an in vitro SUMOylation assay and contrasted their response with that of PDE4B2, which we expected on the basis of the above reported studies not to become SUMOylated. Proteins were transcribed in vitro and labelled with [ 35 S]methionine before being incubated with recombinant SAE (E1), UBC9 (E2), SUMO and an ATP-generating system. For both PDE4D isoforms a single novel species of the increased molecular mass expected for SUMOylation (approx. 25 kDa) was detected only in the presence of all assay components (Figure 3a) . In contrast, no such novel retarded species was evident using PDE4B2 (Figure 3b) , indicating further that PDE4D, but not PDE4B isoforms, are targets for SUMOylation.
Lys 323 is the sole SUMOylation site on PDE4D5
To determine whether SUMO modification of PDE4 isoforms is directed through the potential SUMO site within the conserved catalytic region, we repeated both the in vivo and in vitro SUMOylation assay protocols using a mutant form of PDE4D5 (PDE4D5-K323R) that had the putative acceptor Lys 323 mutated to an arginine residue. The PDE4D5-K323R mutant was generated as a 35 S-labelled species and subjected to an in vitro SUMOylation reaction (Figure 4a) . A VSV-tagged PDE4D5-K323R mutant form was expressed in HEK-293 cells together with HA-tagged PIASy (Figure 4b) . In neither instance did we observe a more slowly migrating species arising, signifying that SUMOylation of PDE4D5 was ablated by the single point substitution of Lys 323 to arginine. These results indicate that PDE4D5 is SUMOylated at a single site, namely Lys 323 . In addition, in vitro SUMOylation of an alanine-scanning peptide array (Figure 4c ) encompassing the putative SUMO site on PDE4D5 illustrated that Lys 323 was crucial for SUMO conjugation. Furthermore, we found that alanine substitution of either the hydrophobic residue at position 1 (V322A) or the acidic amino acid at position 4 (E325A) in the SUMO consensus motif (NDSM) both severely attenuated SUMOylation (Figure 4c ). In contrast with this, mutations of the amino acids at positions 6 and 7, which make up an 'acidic patch' (E327A/D328A) in the NDSM, appeared to have little effect on in vitro SUMOylation of this peptide derived from PDE4D5 (Figure 4c ). 
SUMOylation enhances activation of PDE4D5 by PKA phosphorylation and attenuates PDE4D5 inhibition by ERK phosphorylation
Previous studies have illustrated that the constitutive activity of PDE4D5 can be regulated by phosphorylation through both PKA and ERK [15, [40] [41] [42] . PKA phosphorylation of PDE4D5 in UCR1 results in an activation of PDE catalytic activity, whereas phosphorylation by ERK, occurring within the catalytic region, causes inhibition [5, 15, 40, 42] . We thus set out to determine whether SUMOylation could alter the constitutive activity of PDE4D5 and, furthermore, whether modification by SUMO might reprogramme the activity changes triggered by PKA and by ERK phosphorylation. To do this, recombinant GST-PDE4D5 was pre-SUMOylated in vitro before incorporation into kinase assays containing active forms of either PKA or ERK. We first demonstrated that in vitro SUMOylated PDE4D5 migrated through the gel more slowly than native (untreated control) PDE4D5, suggesting that efficient SUMOylation of this species had taken place (Figures 5a and 5c ). After in vitro phosphorylation with PKA, samples were blotted for phosphorylation by PKA using an anti-phospho-PKA substrate antibody, whereas phosphorylation by ERK was monitored using an anti-phospho-serine antibody. Both SUMOylated (upper band) and native PDE4D5 (lower band) appeared to be equally well phosphorylated by either PKA or ERK, suggesting that the conjugation of SUMO had neither enhanced nor hindered access of the kinases to their substrates or their action (Figures 5a  and 5c ). To reinforce these results, the phosphorylation kinetics of PDE4D5, PDE4D5-K323R and SUMO-PDE4D5 were monitored using a phospho-antibody raised against the PKA site in UCR1 [40, 43] after treatment of HEK-293 cells with the adenylate cyclase activator forskolin and the non-selective PDE inhibitor IBMX (isobutylmethylxanthine) (Figure 5d ) to increase cAMP levels and activate PKA [40] . The phosphorylation of PDE4D5, PDE4D5-K323R and SUMO-PDE4D5 species all followed an identical time course, suggesting that, once again, SUMOylation did not affect the phosphorylation kinetics of PDE4D5.
Next, we set out to determine the PDE catalytic activity of these various phosphorylated species using equal amounts of the various isoforms as determined immunologically with an anti-VSV antibody. Modification of PDE4D5 by SUMO had no effect (< 9 % change; n = 3) on the constitutive activity of PDE4D5 ( Figure 5b ). As reported previously, PKA phosphorylation produced a marked increase in PDE activity, whereas phosphorylation by ERK elicited approx. 50 % inhibition [16, 44] . Surprisingly, however, SUMOylation acted in different ways and the net outcome was to maintain maximally activated PDE4D5. First, activation of PDE4D5 by PKA phosphorylation was augmented by SUMOylation, amplifying activity from approx. 275 + − 12 % of control (100 %) for the PKAphosphorylated species alone to approx. 400 + − 49 % of control (Figure 5b ) for the species that was both PKA-phosphorylated and SUMOylated (mean + − S.D.; n = 3). Secondly, ERK inhibition of PDE4D5 was markedly attenuated by SUMOylation, with PDE4D5 activity now little changed from that of basal levels (Figure 5b) . When using either PKA or ERK to phosphorylate PDE4D5, there appeared to be no observable difference in the phosphorylation status of SUMO-modified PDE4D5 compared with native PDE4D5. This suggests that SUMOylation acts to change the conformation of PDE4D5 so as to reprogramme the functional output of these phosphorylation events in terms of altering the response of the catalytic unit to regulatory inputs.
SUMOylation of PDE4D5 reprogrammes cAMP signalling in COS1 and HEK-β2 cells
Post-translational modification of PDE4D5 by SUMO dually attenuates ERK-induced inhibition and enhances PKA-mediated activation of this cAMP-specific PDE in vitro ( Figure 5 ). To determine whether these effects had functional correlates in living cells, we first investigated the intracellular cAMP levels in COS1 cells that had been transfected to overexpress recombinant PDE4D5 such that, as found previously [16] , its activity represented >98 % of the total cAMP PDE activity in these cells. As noted previously by us [16] , EGF (epidermal growth factor) treatment, in causing ERK phosphorylation and inhibition of the activity of the recombinant, predominating PDE4D5, engenders a transient increase in cAMP that peaks at 10 min ( Figure 6 ). Interestingly, however, the amplitude of the EGFmediated increase in intracellular cAMP was significantly blunted upon co-transfection with PIASy to cause the SUMOylation of Bacterially expressed recombinant PDE4D5-GST was purified and SUMOylated using the SUMOylation kit before incorporation into kinase assays containing active PKA (a) or ERK (b). Samples were then immunoblotted for PDE4D5 (upper panels) and phosphorylation of PKA consensus (a) or phospho-serine (b) (lower panels). The PDE4 activity of all samples was determined using an established PDE assay (c). Results are means + S.E.M. for three independent experiments. Statistical analysis was performed using Student's t test. *P < 0.05, ***P < 0.001. (d) HEK-293 cells were transfected with HA-PIASy and co-transfected with either PDE4D5 (lower set) or PDE4D5 K323R (upper set) and treated with IBMX (100 μM) and forskolin (10 μM) for the indicated times. Cell lysates were then blotted for PIASy (HA), PKA phosphorylated PDE4 (P-UCR1), PDE4D or SUMO. Experiments are typical of those repeated three times.
PDE4D5, which is consistent with the SUMOylated fraction of PDE4D5 being less prone to ERK-directed inhibition (Figure 6a) . The EGF-mediated increase in intracellular cAMP was also completely abolished by pre-treatment with the MEK inhibitor PD98059, being consistent with an effect mediated by ERK (Figure 6a ). No effect of PIASy co-transfection was evident in cells transfected with the VSV-tagged PDE4D5-K323R mutant form (results not shown).
One functional output arising from an enhanced PKA activation of PDE4D5 is the lowering of localized cAMP in the vicinity of the β 2 AR [18] [19] [20] . Studies from our laboratory, using both dominantnegative and siRNA (small interfering RNA) approaches, have shown that active PDE4D5 is an essential component of the desensitization process regulating the β 2 AR following agonist stimulation [19] . This relates to the ability of β-arrestin-recruited PDE4D5 to regulate the phosphorylation of the β 2 AR by a locally acting fraction of PKA that is tethered to the β 2 AR by AKAP79 (A-kinase-anchoring protein 79) [18] [19] [20] . In the present study, we noted that co-transfection of PDE4D5 with PIASy into HEK-β2 cells, which stably overexpress the β 2 AR, caused isoprenaline to elicit less PKA phosphorylation of the receptor at peak activation (5 min) when compared with identical cells overexpressing PDE4D5 alone (Figure 6b ). No effect of PIASy co-transfection was evident in cells transfected with the VSV-tagged PDE4D5-K323R mutant form (results not shown). Presumably, the dual action of SUMO in both enhancing the activation of the PDE4 by PKA while concomitantly preventing inactivation via ERK phosphorylation results in greater hydrolysis of the cAMP pool near to the β 2 AR which, in turn, leads to an associated down-regulation of localized PKA activity.
DISCUSSION
SUMO has been shown to have an important role in many biological processes including DNA repair, transcription and the cell cycle [23] with dysregulated SUMOylation being linked to diseases such as cancer, diabetes and neurological disorders [24] . (a) COS1 cells were transfected with VSV-tagged PDE4D5 or a combination of VSV-tagged PDE4D5 and HA-PIASy. Cells were then treated with EGF for the times indicated. One set of cells, which had been transfected with a combination of VSV-tagged PDE4D5 and HA-PIASy, was pre-treated with the MEK inhibitor PD98059 (20 μM) for 10 min before EGF treatment. Cells were harvested and lysates were analysed for cAMP concentrations as described in the Experimental section. Statistical analysis was performed using Student's t test, on results from three experiments. *P < 0.05. (b) HEK-β2 cells were transfected with VSV-tagged PDE4D5 or a combination of VSV-tagged PDE4D5 and HA-PIASy. Cells were then treated with isoprenaline (Iso; 10 μM) for the times indicated. Cell lysates were probed with antibodies raised against PKA-phosphorylated β 2 AR (Ser 345 , Ser 346 ), total β 2 AR, SUMO and VSV. The amount of relative phosphorylation of the β 2 AR was quantified using densitometry and results are means + S.E.M. (n = 3). Statistical analysis was performed using Student's t test. **P < 0.01.
In the present paper, we report, for the first time, a novel potential regulatory function for SUMO within the cAMP signalling pathway. This involves the SUMOylation of the cAMP-degrading long PDE4D and PDE4A isoforms at a single site within their conserved catalytic unit.
Post-translational modification of PDE4 enzymes by PKAand ERK-mediated phosphorylation can confer functional changes in terms of alterations in enzyme activity status, conformation and interaction with various partner proteins (see, e.g., [15, 16, 40, 44, 45] ), with PKA-mediated activation of PDE4 long isoforms having a pivotal role in the desensitization of cells to cAMP signalling [15] . Moreover, studies utilizing novel genetically encoded cAMP reporters have shown that much of the specificity of function achieved by cAMP produced by adenylate cyclase in response to agonists for different G scoupled receptors is determined through the control of spatially discrete pools of cAMP achieved by differently sequestered PDE4 isoforms, thereby underpinning compartmentalized cAMP signalling [6, 7, 46, 47] .
Modification by SUMO does not alter the constitutive ability of PDE4 enzymes to hydrolyse cAMP. Instead, we show in the present study that SUMOylation serves to both enhance PKAdirected activation and negate ERK-induced inhibition ( Figure 5 ), processes that have in common an absolute requirement for the regulatory UCR1 domain [12, 16, 42, 44] . As Conti and colleagues showed [48] , we confirm in the present study that PKA-mediated phosphorylation provides a critical component for the cellular desensitization mechanism to cAMP by activating PDE4 long isoforms and thereby conferring transience on the increase in cAMP caused by ligands that activate adenylate cyclase. We show here, however, that such transience is markedly pronounced in cells where PDE4D5 SUMOylation is triggered, indicating that this modification has the ability to amplify the cellular desensitization process towards cAMP ( Figure 6 ). Intriguingly, SUMOylation is restricted to long isoforms from the PDE4A and PDE4D subfamilies; PDE4B and PDE4C enzymes lack the key acceptor lysine residue central to the classical SUMO consensus motif ( Figure 1 ) and short isoforms lack a crucial docking site for the SUMO E3 ligase PIASy. Thus only in signalling complexes involving PDE4D and PDE4A long isoforms would SUMOylation amplify activation due to PKA phosphorylation. This might therefore confer specific negative regulation of cAMP levels in distinct microdomains due to the selective sequestration of long PDE4A and PDE4D isoforms in concert with active SUMOylation machinery.
In addition to amplifying the effect of PKA-mediated phosphorylation on PDE4A and PDE4D, we also show in the present study that SUMO modification reprogrammes the functional outcome of phosphorylation by ERK. This effect is restricted to PDE4D long isoforms, however, because PDE4A enzymes do not contain the ERK consensus motif in the third subdomain of their catalytic unit and therefore cannot be phosphorylated by this kinase [15] . Also, as stated above, short PDE4Ds cannot bind SUMO E3s in order to increase the requisite fidelity for SUMOylation to ensue. Thus, uniquely, it is PDE4D long isoforms where SUMOylation negates the inhibitory action of ERK phosphorylation (Figure 4) .
Further work is required in order to define the mechanistic basis underpinning the functional consequences of PDE4A and PDE4D SUMOylation. However, it is conceivable that the SUMO subunit interfaces with UCR2 to stabilize interactions with the phosphorylated UCR1, while destabilizing interactions with the ERK phosphorylation site. The basis for this proposal is the current consensus that UCR2 folds on to the core catalytic domain to exert an auto-inhibitory action [49, 50] . PKA-mediated phosphorylation of UCR1 establishes an interaction between the two UCR modules that either removes UCR2 from the core catalytic unit or alters its folding so as to remove the inhibitory action [13] . Phosphorylation by ERK, on the other hand, may stabilize UCR2 in its inhibitory conformation. Given that the SUMO subunit is tethered to a site on the core catalytic domain proximal to the connection to UCR2, a direct interaction between SUMO and the UCR modules would be reasonable. It is also possible that SUMOylated PDE4s become novel interacting partners or substrates for proteins that contain conserved SIMs (SUMO-interacting motifs) [51] . SIM-directed interactions are known to modify the turnover, conformation and localization of SUMOylated enzymes and may be the reason that only a small proportion of a particular protein is modified at any given time. To our knowledge, none of the known PDE4-interacting proteins contain SIMs; however, we cannot rule out this possibility for novel interactions that remain undiscovered.
In summary, we have discovered that the long PDE4D and PDE4A isoforms, but not isoforms from the PDE4B and PDE4C subfamilies, have the potential to become SUMOylated. A major functional outcome of this modification is to amplify PDE4 activation elicited by PKA phosphorylation, thereby contributing to the cellular desensitization system attributed to PKA phosphorylation of PDE4. Additionally, SUMOylation negates inhibitory regulation of long PDE4D isoforms caused by ERK phosphorylation, thereby ensuring that SUMO-modified PDE4 remains fully active or activated. Finally, we have shown that SUMOylation enhances the activation of PDE4D5 following activation of the β 2 AR and that this results in less PKA-mediated phosphorylation of the receptor. In this regard, SUMO modification may represent a novel means to increase desensitization efficiency of this receptor. It is worth noting that SUMO modification of PDE4 isoforms may have consequences outside of β-adrenergic signalling. For example, PDE4A isoforms have been shown to modulate cAMP signals in T-cells, to potentiate their activation [52] , to control functioning of the p75 neurotrophin receptor (p75NTR) [53] and to be involved in cognitive deficits associated with sleep deprivation [54] .
